Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about updates on Scube3 related to hair loss. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

Sodium Laureth Sulfate (SLS) in shampoos and its potential impact on thinning hair. The user follows a regimen of shampoo, keto shampoo, and conditioner, seeking suggestions for better products.

The user is considering switching from a stamp to a pen for hair treatment due to poor results with the stamp. They are concerned about the availability of pen refills and are seeking better outcomes with the pen.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.

A user bought questionable RU58841 powder from AliExpress and seeks a way to test its composition in Europe. Another user suggests using Janoshik for testing.

The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.

A user shared a 9-month update on using 0.25mg finasteride daily for hair maintenance, reporting no significant side effects and considering whether to add other treatments like a dermastamp or ketoconazole. The user has not used minoxidil, believes it's unnecessary unless hair loss is severe, and occasionally takes biotin supplements.

A user experienced facial swelling while taking spironolactone for androgenic alopecia, despite its diuretic properties. They are unsure about increasing the dose due to this side effect.

User shares 1-month vs 9-month finasteride results for hair loss. Commenters discuss photo angles, hair regrowth, and side effects.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

A 29-year-old male experienced hair regrowth using minoxidil 5% foam and KX826 after stopping finasteride due to side effects. He applies both treatments once daily and reports no side effects from the current regimen.

The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.

The user experienced negative side effects from oral minoxidil, including cardiac issues and excessive sweating, and decided to switch to topical minoxidil while using other treatments like RU58841, Setipiprant, Azelaic acid, and latanoprost. Another user suggested splitting the oral minoxidil dose to reduce side effects.

A user is waiting for pyrilutamide delivery and is seeking reviews, especially regarding side effects. No reviews have been mentioned in the conversation.

The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.

The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.

The conversation discusses a hair regrowth treatment containing Minoxidil, Procapil, Sandalore, and caffeine. The focus is on evaluating the effectiveness of this product available on eBay.

A user who was part of an ongoing trial for a prolactin blocker and had regrowth, but the progress photos were not shared due to negative reactions from other users. Treatments mentioned include HMI-115, Minoxidil, Finasteride, and RU58841.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

9-month progress using Minoxidil and Finasteride for hair loss. Users discuss treatments, vitamins, and microneedling.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

Pyrilutamide is seen as a last hope for those who can't take finasteride, with promising results reported. However, there's uncertainty about the quality and consistency of Pyrilutamide from black market sources.

The conversation discusses the sale of a premixed KY19382 solution for research purposes, highlighting previous unsuccessful group buys and the formulation process. Prices and purchasing options for KY19382 solutions and powder are provided.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.

The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.